Bone Cement & Glue Market - Global Forecast 2026-2032

The Bone Cement & Glue Market size was estimated at USD 2.55 billion in 2025 and expected to reach USD 2.68 billion in 2026, at a CAGR of 5.41% to reach USD 3.69 billion by 2032.

Bone cement and bone glue are critical orthopedic biomaterials used to stabilize implants, fill bone voids, support vertebral compression fracture procedures, and enable fixation in trauma, arthroplasty, spinal surgery, and dental applications. The category is led by polymethyl methacrylate (PMMA) bone cement, calcium phosphate and calcium sulfate cements, bioactive glass-based materials, and emerging adhesive technologies designed to improve osseointegration, infection control, handling characteristics, and procedural efficiency. Demand is structurally supported by the global burden of musculoskeletal disorders, rising joint replacement volumes, aging populations, sports and road-trauma injuries, and the clinical need for faster fixation in minimally invasive procedures. According to the World Health Organization, musculoskeletal conditions affect approximately 1.71 billion people worldwide, while osteoarthritis alone is among the leading contributors to disability, reinforcing the importance of durable orthopedic fixation and bone repair solutions. For manufacturers, providers, and procurement leaders, the bone cement and glue landscape is increasingly shaped by regulatory scrutiny, antimicrobial stewardship, material science innovation, and value-based healthcare priorities focused on surgical outcomes, revision reduction, and patient mobility.

The bone cement and glue industry is undergoing a material and clinical transformation as orthopedic care shifts from traditional fixation toward biologically supportive, procedure-specific, and infection-aware solutions. PMMA remains widely used in hip and knee arthroplasty due to established mechanical performance and long clinical familiarity, but product development is increasingly focused on lower monomer exposure, improved viscosity control, optimized working time, and antibiotic-loaded formulations for infection-risk management. Calcium phosphate and calcium sulfate cements are gaining attention in bone void filling because of their osteoconductive profile and gradual remodeling behavior, while bioactive and composite materials are being evaluated for better integration with host bone. Minimally invasive spine procedures, including vertebroplasty and kyphoplasty, continue to influence demand for injectable cements with predictable radiopacity, flow behavior, and setting performance. At the same time, surgical teams are emphasizing standardized mixing, delivery systems, and closed-vacuum handling to reduce variability and occupational exposure. The industry is also responding to tighter medical device regulations, post-market surveillance requirements, biocompatibility testing expectations, and increasing evidence demands from hospitals and payers. These shifts are redefining competitiveness around clinical evidence, infection prevention, ease of use, and compatibility with modern surgical workflows rather than product availability alone.

Artificial intelligence is becoming a practical enabler across the bone cement and glue value chain, particularly in product development, surgical planning, quality control, and post-market evidence generation. In materials research, AI-assisted modeling can help screen polymer blends, ceramic compositions, curing profiles, porosity characteristics, and mechanical performance variables before physical prototyping, reducing experimental burden while improving formulation precision. In clinical settings, AI-enabled imaging and surgical planning tools can support assessment of bone quality, implant positioning, fracture morphology, and vertebral body anatomy, helping clinicians select appropriate cement volume, viscosity, and delivery timing. AI may also improve adverse event detection by analyzing registries, electronic health records, and post-market surveillance data for signals related to loosening, leakage, infection, embolic events, or revision procedures. In manufacturing, machine vision and predictive analytics support batch consistency, sterility assurance, packaging inspection, and traceability for regulated orthopedic biomaterials. The cumulative impact is not the replacement of surgeon judgment or regulatory validation, but a stronger evidence ecosystem in which bone cement and glue products can be developed, tested, monitored, and applied with greater precision. Organizations that combine AI with clinical validation, data governance, cybersecurity, and transparent regulatory documentation are better positioned to meet evolving expectations for safety, performance, and reproducibility.

In Asia-Pacific, bone cement and glue adoption is supported by rapidly aging populations, expanding orthopedic procedure capacity, and growing access to joint replacement and trauma care in China, India, Japan, South Korea, Australia, and Southeast Asia. Japan has one of the world’s oldest populations, intensifying demand for fracture care and arthroplasty-related fixation, while China and India face large musculoskeletal disease burdens and rising surgical infrastructure investment. North America remains highly evidence-driven, with widespread use of cemented and cementless fixation strategies determined by patient age, bone quality, implant type, and surgeon preference; the region also places strong emphasis on infection prevention, regulatory compliance, and outcomes measurement through registries and hospital quality programs. Latin America shows increasing use of orthopedic biomaterials through public and private healthcare expansion, with Brazil and Mexico serving as important procedural centers, although reimbursement variation and access disparities influence product selection. Europe is shaped by mature arthroplasty practice, stringent medical device regulation under the EU Medical Device Regulation framework, and strong focus on clinical evidence, traceability, and post-market surveillance. The Middle East is expanding advanced orthopedic and spine services through hospital infrastructure development, medical tourism, and specialist centers, particularly in Gulf economies, while Africa presents a more heterogeneous landscape where trauma care needs are significant but access to specialized orthopedic implants and biomaterials varies by country, facility capability, and procurement systems.

Across ASEAN, demand for bone cement and glue is linked to urbanization, rising noncommunicable disease prevalence, road-traffic trauma, and gradual expansion of orthopedic surgical capacity in countries such as Indonesia, Thailand, Vietnam, Malaysia, the Philippines, and Singapore. The GCC is characterized by high investment in tertiary care, medical tourism, and advanced orthopedic centers, with procurement decisions often influenced by international regulatory approvals, surgeon training, and premium hospital standards. The European Union provides one of the most regulated environments for orthopedic biomaterials, where compliance with medical device rules, clinical evaluation, unique device identification, and post-market performance monitoring strongly shapes market access and product lifecycle management. BRICS countries combine large patient pools with varying levels of healthcare infrastructure, creating opportunities for cost-effective, evidence-backed bone cement and glue solutions that address arthroplasty, trauma, spine, and dental indications while meeting local registration requirements. G7 countries generally exhibit mature orthopedic practice, established hospital purchasing systems, and higher expectations for clinical data, antimicrobial stewardship, and manufacturing quality. NATO member countries, many of which overlap with advanced healthcare economies, also demonstrate relevance for trauma preparedness and reconstructive surgery capabilities, where reliable orthopedic fixation materials are important for civilian and defense-related medical readiness.

The United States is defined by high procedural sophistication, extensive orthopedic specialization, and strong oversight of medical devices, with bone cement and glue usage shaped by arthroplasty volumes, spine interventions, infection control protocols, and hospital value analysis committees. Canada emphasizes publicly funded care pathways, outcomes quality, and access across provinces, while Mexico combines public healthcare demand with growing private orthopedic services and cross-border medical care. Brazil is a major Latin American orthopedic center with substantial trauma and joint reconstruction needs, whereas the United Kingdom prioritizes registry-driven evidence, procurement governance, and clinical outcomes in arthroplasty and fracture care. Germany, France, Italy, and Spain all maintain advanced orthopedic ecosystems where cement selection is influenced by surgeon preference, aging demographics, regulatory compliance, and hospital purchasing frameworks. Russia has a large musculoskeletal and trauma care requirement, though access and procurement conditions can vary across regions. China is expanding orthopedic capacity in line with hospital modernization, population aging, and rising access to joint replacement and spine procedures, while India is experiencing increasing demand from trauma, osteoarthritis, and private hospital expansion, with cost-effectiveness remaining a key adoption factor. Japan’s super-aged demographic profile supports sustained need for fracture fixation and joint reconstruction materials, and Australia benefits from established arthroplasty registry practices and high-quality surgical standards. South Korea combines advanced hospital infrastructure, medical technology adoption, and strong orthopedic and spine care capabilities, supporting demand for high-performance bone cement and glue products with proven safety and handling characteristics.

Industry leaders should prioritize differentiated, clinically validated formulations that address infection prevention, controlled setting time, radiopacity, mechanical strength, and predictable handling across arthroplasty, spine, trauma, and dental procedures. Investment in antimicrobial-loaded bone cement should align with antibiotic stewardship principles, local resistance patterns, and clear clinical protocols to avoid inappropriate use. Manufacturers should strengthen regulatory documentation, biocompatibility testing, post-market surveillance, and real-world evidence programs to meet increasingly rigorous expectations from hospitals and authorities. Product design should focus on usability, including closed mixing systems, delivery precision, reduced fumes, lower waste, and compatibility with minimally invasive surgical workflows. Regional strategy must be tailored to reimbursement systems, surgeon training requirements, infrastructure readiness, and procurement models rather than relying on a uniform global approach. Partnerships with hospitals, academic orthopedic centers, and professional training programs can improve procedural consistency and support adoption of advanced cements and adhesives. Companies should also build resilient supply chains for monomers, ceramics, antibiotics, sterile packaging, and delivery components while ensuring traceability and quality controls. Finally, digital tools and AI-driven analytics should be integrated responsibly to support product development, manufacturing quality, and post-market safety monitoring without compromising regulatory transparency or clinical accountability.

This executive summary is developed through a structured secondary research approach focused on verified public sources, clinical literature, regulatory guidance, health system data, and peer-reviewed orthopedic and biomaterials evidence. The analysis considers internationally recognized health information on musculoskeletal disease burden, aging demographics, osteoarthritis, trauma, arthroplasty, infection prevention, and medical device regulation. Source types include government health agencies, international health organizations, orthopedic registries, regulatory authority publications, scientific journals, standards-related documentation, and hospital practice guidance where publicly available. The methodology emphasizes triangulation across clinical, regulatory, and healthcare infrastructure indicators to identify durable industry themes without relying on market sizing, market share, or forecasting. Regional, group, and country insights are interpreted through evidence-backed factors such as demographic transition, surgical capacity, regulatory frameworks, reimbursement conditions, orthopedic disease burden, and hospital procurement practices. The analysis excludes unsupported claims and avoids company-specific discussion to maintain objectivity and relevance for strategic decision-making in the bone cement and glue industry.

Bone cement and glue remain essential to modern orthopedic, spine, trauma, and dental care as healthcare systems respond to aging populations, musculoskeletal disability, injury burden, and the need for reliable fixation and bone repair. The industry is moving beyond conventional cement performance toward evidence-backed, infection-aware, biologically compatible, and workflow-friendly solutions. Regional growth dynamics vary widely, with mature markets emphasizing clinical evidence and regulatory rigor, while emerging markets prioritize access, affordability, and surgical capacity expansion. Artificial intelligence, real-world evidence, and advanced materials science are expected to strengthen formulation development, quality assurance, and clinical monitoring, provided they are implemented within robust regulatory and ethical frameworks. For industry participants, success will depend on delivering safe, validated, easy-to-use products that improve procedural consistency and patient outcomes while meeting the operational demands of hospitals and surgeons worldwide.